MMRF’s Personalized Medicine Initiative has been developed to allow molecular characterization of multiple myeloma patients and thus enforce the development of new, targeted treatments.
Onyx is believed to provide scientific and financial support for the comprehensive research initiative in multiple myeloma.
MMRF founder and CEO Kathy Giusti said through this alliance it seeks to gain further insights into development and progress of the disease in order to obtain a cure for it.
"Onyx is an invaluable partner who shares our passion for rapidly translating new insights into breakthrough therapies to bring us closer to a cure," Giusti added.